IgA Tarpeyo denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for iga tarpeyo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denies Tarpeyo as Not FDA-Approved — and Why That Denial Is Appealable

A "not FDA-approved" denial for Tarpeyo from UnitedHealthcare is one of the most straightforwardly incorrect denial types you can receive, because Tarpeyo holds full FDA approval for the treatment of primary IgA nephropathy. This denial category is most commonly triggered by one of three administrative errors: an outdated formulary database that has not incorporated the drug's approval, a coding mismatch between the diagnosis code on the claim and the approved indication, or a clerical error in claim processing.

Before investing effort in a detailed clinical appeal, confirm that the prescription was submitted with the correct diagnosis code and that your plan's pharmacy benefit manager has updated its database. If an administrative fix resolves the issue, document the correction. If UHC maintains the denial after correction, proceed to formal appeal.

## Your Federal Appeal Rights

• ACA §2719: Non-grandfathered plans are required to offer internal appeals and binding external review. An external IRO reviewer will examine the FDA approval status independently and is not bound by the plan's internal determination.
• ERISA §503: Employer plan members are entitled to a full-and-fair review, including access to the specific rationale and clinical criteria the plan used.
• Timeline: Internal appeals are generally due within 180 days of the denial notice. External review requests are typically available for approximately four months after a final internal denial. Expedited review is available if standard timing poses a risk to your kidney health.

## Documentation to Gather Before You Appeal

1. FDA approval documentation — print or download the FDA's official drug-approval record for Tarpeyo, showing the approval date and the approved indication verbatim. 2. Prescribing information — attach the complete FDA-approved prescribing label (package insert), which constitutes the regulatory record of approval. 3. Correct diagnosis coding — confirm with your prescriber's billing office that the claim was submitted with the appropriate ICD-10 code for IgA nephropathy and that it matches the approved indication. 4. Nephrologist's letter — a brief letter confirming the diagnosis and that the prescription is for the FDA-approved indication. 5. UHC's denial rationale — request the specific basis for the denial in writing; if UHC acknowledges an internal database or coding issue, that acknowledgment itself supports overturning the denial.

## Criteria-Mapping Structure

Keep this appeal letter concise and factual. Lead with the FDA approval date and indication as stated on the official label — one paragraph. Follow with a direct rebuttal of each specific reason UHC cited. Attach the FDA approval record as Exhibit A and the prescribing label as Exhibit B. If the denial was administrative, document the correction and request reprocessing. If UHC does not reverse on internal appeal, proceed immediately to external review.